Skip to main content

ITC Administrative Law Judge Finds 3Shape Infringes Align’s Scanner-Related Patents

Written by Customer Service on . Posted in Public Companies.

ALJ recommends exclusion and cease and desist order against infringing 3Shape productsInitial Determination Finds 3Shape Infringes 7 of the 9 Claims Asserted by Align, and that 6 of the 9 Asserted Claims Are ValidFinds Violation of Section 337 and Recommends Import Exclusion of Infringing 3Shape ProductsRecommends Commission Issue Cease and Desist Order Directed to the Sale of Infringing 3Shape ProductsSAN JOSE, Calif., May 01, 2020 (GLOBE NEWSWIRE) — Align Technology, Inc. (NASDAQ: ALGN) today announced that on April 30, 2020 an Administrative Law Judge (ALJ) with the United States International Trade Commission (ITC) issued an Initial Determination regarding her investigation of 3Shape A/S, 3Shape Trios A/S, and 3Shape Inc.’s (“3Shape”) infringement of Align’s patents. The ALJ determined that 3Shape infringes 7 of the 9 patent claims asserted by Align, found valid 6 of the 9 claims asserted by Align, and found a violation of Section 337 stemming from 3Shape’s infringement of 4 claims in 2 of Align’s asserted patents. The ALJ recommended an exclusion order and cease and desist order be entered against 3Shape’s unlawful importation. 
“We are pleased that the Initial Determination confirms the intellectual property rights we asserted against 3Shape,” said Julie Coletti, Align Technology senior vice president, chief legal and regulatory officer. “Our continuing investment in innovation enables technologies and products that help our doctor customers and their patients. We remain committed to protecting this investment and preventing the unauthorized use of our intellectual property as part of our global strategy.”The Initial Determination is now subject to review by the Commissioners at the ITC. Align may file a contingent petition for review of any findings it believes are incorrect. 3Shape may also petition for review of the Initial Determination. The Commission will then decide whether to review portions of or the entire Initial Determination.The claims filed by Align in the U.S. District Court in Delaware alleging infringement of the same patents, remain stayed pending the Final Determination and any related appeals. Align intends to pursue damages and permanent injunctions in the U.S. District Court. Furthermore, Align has asserted an additional 26 patents against 3Shape in 6 U.S. District Court cases.   About Align Technology, Inc.
Align Technology designs and manufactures the Invisalign® system, the most advanced clear aligner system in the world, iTero® intraoral scanners and services, and CAD/CAM software. Align has helped treat over 8 million patients with the Invisalign system and is driving the evolution in digital dentistry with the iTero intraoral scanner and exocad CAD/CAM software − modernizing today’s practices by enabling enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies. Visit www.aligntech.com for more information.For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.